Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in riā¦ read more
Healthcare
Drug ManufacturersāGeneral
54 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$67.01
Price+2.35%
$1.54
1Y
Price
Market Cap
$136.882b
Large
Price/Earnings 3y Avg5y Avg
11.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+38.1%
EBITDA Margin+25.6%
Net Profit Margin+23.8%
Free Cash Flow Margin+38.1%
EBITDA Margin+25.6%
Net Profit Margin+23.8%
Free Cash Flow MarginRevenue
$49.187b
+2.1%
1y CAGR+3.1%
3y CAGR+1.7%
5y CAGREarnings
$9.282b
+31.6%
1y CAGR-0.4%
3y CAGR+6.4%
5y CAGREPS
$4.54
+31.6%
1y CAGR-1.5%
3y CAGR+6.6%
5y CAGRBook Value
$22.319b
$87.634b
Assets$65.315b
Liabilities$43.120b
DebtDebt to Assets
49.2%
2.6x
Debt to EBITDAFree Cash Flow
$11.440b
-10.9%
1y CAGR-2.9%
3y CAGR-0.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company